Stock listing

Munich:AX9 Akebia Therapeutics, Inc. Aktie

German listing (Munich) of Akebia Therapeutics, Inc. · home listing NASDAQ:AKBA

Follow Akebia Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:AKBA

$0.68 USD +0.01 (+1.5%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AKBA

Past year -78.5% · daily closes, Oct 20, 2025 – Oct 19, 2026, adjusted for splits
Day range
$0.67 – $0.70 USDOct 19, 2026
Volume
7.76M sharesOct 19, 2026
Market value
$188.5M USDAt the close on Oct 19, 2026 · price × 277.1M shares outstanding
52-week range
$0.666 – $3.20 USDLowest and highest trades, Oct 20, 2025 – Oct 19, 2026
Akebia Therapeutics, Inc. logo
Ticker
Munich:AX9
Asset type
Stock
Exchange
Munich
Currency
EUR

What changed lately

Calls

Replays

  • Akebia Therapeutics (NASDAQ:AKBA) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 4:30 PM ET

    Watch Transcript
  • Akebia Therapeutics (NASDAQ:AKBA) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:00 AM ET

    Watch Transcript
  • Akebia Therapeutics (NASDAQ:AKBA) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

All Akebia Therapeutics, Inc. news

Decks

Akebia Therapeutics, Inc. on 6ix

News releases
31 in the last 12 months · 181 in all · newest Oct 7, 2026 · oldest 2019
Calls
21 calls with a replay · 21 with a transcript · latest Aug 5, 2026
Decks
17 decks · latest Apr 2, 2026

Where Akebia Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AKBA · Home listingNASDAQUnited StatesUSD
Tradegate:AX9TradegateGermanyEUR
LS Exchange:A1XF0SLS ExchangeGermanyEUR
BOATS:AKBABOATSUnited StatesUSD
Lang & Schwarz:A1XF0SLang & SchwarzGermanyEUR
gettex:AX9gettexGermanyEUR
Hamburg:AX9HamburgGermanyEUR
BX Swiss:AX9BX SwissSwitzerlandCHF
Dusseldorf:AX9DusseldorfGermanyEUR
Frankfurt:AX9FrankfurtGermanyEUR
Munich:AX9 · This pageMunichGermanyEUR
Stuttgart:AX9StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Akebia Therapeutics, Inc.